Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: September 02, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
Journal: The New England journal of medicine
Published: June 01, 2026
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.
Journal: The New England journal of medicine
Published: May 06, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Journal: bioRxiv : the preprint server for biology
Published: December 25, 2025
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.
Journal: Journal for immunotherapy of cancer
Published: December 23, 2025
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.
Journal: Nature medicine
Published: November 25, 2025
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.
Journal: NPJ precision oncology
Published: July 28, 2025
Disrupted molecular glue complex drives RAS inhibitor resistance.
Journal: Cell
Published: June 03, 2025
Gemcitabine-induced myositis in a patient with pancreatic cancer.
Journal: BMJ case reports
Published: January 22, 2025
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.
Journal: JAMA network open
Published: January 08, 2025
Last Updated: 09/26/2026